



Rec'd PCT/PTO 30 JUNE 2003 / 000097#
10/600559



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 13 FEB 2003


WIPG PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

R. Mahoney

Dated

31 JAN 2003

BEST AVAILABLE COPY



Patents Act 1977
(Rule 16)



15 JAN 02 14:57:03-4 D02847
P01/7700-0:00-0200721.9

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

HL79209/000/GJW/DAN

2. Patent application number

(The Patent Office will fill in this part)

0200721.9

14 JAN 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

University of the West of England, Bristol
Frenchay Campus
Coldharbour Lane, Bristol BS16 1QY

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

6678858001

4. Title of the invention

Toxicity Test

5. Name of your agent (if you have one)

Haseltine Lake & Co.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Imperial House
15-19 Kingsway
London
WC2B 6UD

Patents ADP number (if you know it)

34001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

11

Claim(s)

1

Abstract

1

Drawing(s)

3 + 3 Encl

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application

Signature

Date

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr Gillian Whitfield

[0117] 910 3200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 50051
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

TOXICITY TEST

The present invention relates to an *in vitro* toxicity assay using spheroids.

5 Spheroids have significant potential to be used as *in vitro* models to test the toxicity of compounds at various concentrations. The use of spheroids in an *in vitro* model as a repeatable and reliable indicator of toxicity is a desirable alternative to using live animals.

10 The inventors have developed a cell spreading inhibition test based on the observed spheroid cell growth, or "spreading" of cells in spheroids when the spheroids are grown on a suitable surface and at static state i.e. without shaking. As shown in Figure 1, the
15 cells grow out from the surface of the spheroid. It was found that when spheroids are exposed to a toxicant at a certain concentration, cell spreading is inhibited. This inhibition of cell spreading provides an indicator of toxicity.

20 According to a first aspect of the invention, there is provided an *in vitro* toxicity assay comprising:

- a) exposing a spheroid sample to a selected concentration of a compound to be assayed;
- 25 b) incubating the spheroid sample for a suitable period of time; and
- c) observing if spheroid cell spreading inhibition takes place.

30

35

At the selected concentration, if no cell spreading, or very limited spreading, of all the spheroids in the sample is observed relative to a control spheroid not exposed to the compound being assayed, this is
5 considered to be a spreading inhibition positive (+) result. However, if there is observable cell spreading from one or more of the spheroids in the sample, this is a cell spreading inhibition negative (-) result.

10 In the event that partial spreading is observed ie. there is some observable cell spreading in the sample, but not as extensive as in the control, then the assay should be repeated at a higher compound concentration to ensure that a conclusive result can be obtained, ie. a spreading inhibition positive (+) result.

15 When spheroid cell spreading inhibition occurs, this indicates that, at the selected concentration, the compound has a toxic effect on the cell type from which the spheroid sample is derived.

20 As used herein, the term "spheroid" means a three dimensional structure, normally spherical in shape, which does not occur in nature and which consists of a re-aggregate of cells - typically containing 10^3 or more cells - of a tissue or of an organ or formed from cells lines either alone or in combination.

25 The term "tissue" as used herein is taken to mean an organised selection of cells having a common function. The term "organ" is taken to mean an organised collection of "tissues" having a common function. The term "cell line" is taken to mean a continuous cell culture derived
30 from cells subject to transformation or otherwise having acquired to ability to divide continuously.

The "tissue" or "organ" need not be completely intact to be used in the present invention since parts of whole tissues or organs (which may be obtained via biopsies)
35 can be disrupted to individual cells/small groups of cells before being re-aggregated to form spheroids used

in the present invention.

Cells for use in producing spheroids for use in the present invention may be derived from any suitable tissue source, including infected tissue. For spheroids
5 comprising neuronal cells (e.g. brain spheroids), foetal tissue is preferred. For spheroids comprising other cells, tissue from both embryonic/foetal and non-foetal (e.g. adult sources) can generally be used. Liver cells are particularly useful since they can be used to
10 produce spheroids which retain some of the characteristics of the liver e.g. albumin secretion, urea secretion, glucose secretion and can therefore be used to model *in vitro* the metabolism of substances in the liver and to explore general cytotoxic and specific
15 hepatotoxic effects. This is useful, for example, in determining whether or not particular substances are likely to be toxic following metabolism by the liver and/or are directly toxic to the liver cells (i.e. hepatotoxins) or interfere with generic cellular
20 functionality.

Spheroids can, in principle, be produced from any desired tissue or organ from any animal by disrupting a sample of the tissue or organ, preferably to individual cells or to small groups of cells. For example,
25 mechanical disruption such as by gentle trituration through a Pasteur pipette can be employed for retinal and brain tissues. Alternatively, enzymatic digestion methods can be used, for example, for liver cell dissociation.
30 Preferably, the spheroids of the present invention are derived from mammalian tissue or organs, such as from human, rat, mouse, or porcine tissue or organs.

Cells from cell lines may also be used. These may be initially cultured as a monolayer to generate more
35 cells; trypsinization may be used for cell dissociation of a monolayer cell culture.

The spheroids used in the present invention may comprise two or more different cell types, whereby observation of cell spreading inhibition indicates that all the cell types making up the spheroid exhibit a
5 toxic effect in response to the toxicant being tested.

Spheroids used in the present invention may be freshly prepared or may be obtained by thawing cryopreserved spheroids. Spheroids may be cryogenically prepared using methods such as that
10 described in WO98/35021.

The *in vitro* assay of the present invention may be carried out using a series of different selected concentrations of the compound to be assayed, to provide an estimate of the threshold concentration at
15 which the compound becomes toxic to the spheroid cell type.

By carrying out the assay of the present invention using the same compound and different spheroid cell types, it may be possible to determine at what
20 concentrations the compound is toxic to one cell type and not to the other.

Brief Description of the Drawings

Figures 1A to 1C show spheroid cell spreading when spheroids are grown on a surface at static state;
25

Figures 2A to 2C show spheroid spreading in the presence and absence of specific concentrations of galactosamine;
30

Figures 3A to 3C show spheroid spreading in the presence and absence of specific concentrations of propranolol;
35

Figures 4A and 4B show spheroid spreading in the presence of specific concentrations of diclofenac; and

Figures 5A and 5B show spheroid spreading the presence of specific concentrations of paracetamol.

In the following examples, fresh liver or HepG2 spheroids were used. Each test was repeated, to ensure

that the same results were obtained and thereby ensure that the spheroid cell spreading inhibition test (SCSIT) is a reliable indicator of toxicity.

Preparation of liver spheroids

5 Liver spheroids were prepared from the liver of male Wistar rats by a two-step collagenase perfusion method described by Seglen P.O. ((1976). Preparation of isolated rat liver cells. Methods Cell. Biol. 13, 29-38) and modified by Lazar, A.; Peshwa, M.V., Wu, F.J.,
10 Chi, C.M., Cerra, F.B., and Hu, W.S. (1995). Extended liver-specific functions of procine hepatocyte spheroids entrapped in collagen gel. In Vitro Cell Biol Anim. 31, 340-346). Viability of the isolated liver cells was determined by tyrpan blue dye exclusion
15 i.e. an aliquot of isolated liver cells was mixed with an equal volume of trypan blue dye (1.0% w/v in isotonic saline) and incubated at room temperature for a minimum period of 5 minutes. Only isolated liver cell preparations with viability above 80% were used to
20 prepare liver spheroids. The cell suspension was diluted with culture medium (hepatocyte medium supplemented with 5% FCS, 200 mM L-glutamine, 2 ng/ml insulin, 100 U/ml penicillin and 100 µg/ml streptomycin sulfate) to give a cell density of 5×10^5 cells/ml.
25 The diluted cell suspension was dispersed into 6-well plates, 3 ml/well. The plates were incubated at 37°C, in a 5% CO₂ incubator on a gyrotatory shaker (New Brunswick). at an initial rotation speed of 85 rpm for the first 24 hr and 77 rpm thereafter. The plates were
30 rotated at this speed for the duration of the study (up to 45 days, but typically 2-10 days). 1.5 ml of old medium was replaced with 2.0 ml fresh medium for each well every other day. Media exchange was carried out over the duration of the study (up to 45 days, but
35 typically 2-10 days).

Spheroids prepared using this protocol have a

uniform size typically 170 μm , of which >80% are in the range of 160-180 μm .

Preparation of HepG2 spheroids

5 HepG2 cell line (Human Caucasian Hepatocyte Carinomal cells, from ECACC) was cultured as a monolayer in a 75 cm^2 flask at an initial density of 10^2 cells/ cm^2 in a culture medium containing MEM (Sigma) supplemented with 10% FBS, 200 nM L-Glutamine, 100 U/ml
10 penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin (GibcoBril). HepG2 cells of confluent flasks were detached by trypsin and pooled together to be counted by trypan blue dye excretion. The cell suspension was diluted with culture medium (MEM supplemented with 5 % FBS, 200 nM
15 L-glutamine, 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin) to give 1×10^6 cell/ml cell suspension. The cell suspension was plated into 6-well plates, 3ml/well. The plate was placed on a gyrotatory shaker (New Brunswick) at 83 rpm in a 37°C CO₂ incubator for
20 the first 24 h, and then the rotation speed reduced to 77 rpm. After 6 DIV culture, spheroids were ready for use.

EXAMPLE 1

25 3 to 5 freshly prepared spheroids were transferred into each well of a 24 well plate and exposed to galactosamine at various concentrations as detailed in Tables 1 and 2. Two wells were used for each concentration of galactosamine. The spheroids were
30 incubated in Hepatocyte medium (Sigma) supplemented with 10-15% FCS, 200nM L-glutamine, 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin sulfate, and placed in a 5% CO₂ incubator at 37°C and the effects on spheroid cell spreading inhibition observed after 48 hours exposure
35 of the cells to galactosamine:

Table 1 : SCSIT results using fresh liver spheroids

Batch	Control	4mM	10mM	16mM	20mM	40mM
A	-	-	-	-	÷	+
B	-	-	-	-	+	+
C	-	-	-	-	+	+

Table 2 : SCSIT results using fresh HepG2 spheroids

Batch	Control	4mM	10mM	16mM	20mM	40mM
A	-	-	-	+	+	+
B	-	-	-	+	+	+
C	-	-	-	+	+	+

5

- indicates that no spheroid cell spreading inhibition was observed;
+ indicates that spheroid cell spreading was inhibited.

10

Figure 2A shows a control liver spheroid (with no exposure to galactosamine), 48 hours after cessation of rotation. No inhibition of spheroid cell spreading is observed. Figure 2B shows that 48 hours after exposure of a liver spheroid to galactosamine at a concentration of 16 mM, no spheroid cell spreading inhibition is observed. However, Figure 2C shows that 48 hours after exposure of a liver spheroid to galactosamine at a concentration of 40 mM, spheroid cell spreading was inhibited.

15

20

From Table 1, it can be seen that galactosamine inhibits liver spheroid cell spreading at concentrations of 20 mM and higher.

From Table 2, it can be seen that galactosamine

inhibits HepG2 spheroid cell spreading at concentrations of 16 mM and higher.

EXAMPLE 2

- 5 Freshly prepared spheroids were exposed to propranolol at various concentrations as detailed in Tables 3 and 4, and the effects on spheroid cell spreading inhibition observed:

10 Table 3 : SCSIT results using fresh liver spheroids

Batch	Control	62.5µM	125µM	250µM	500µM	1000µM
A	-	-	-	+	+	+
B	-	-	+	+	+	+
C	-	-	+	+	+	+

Table 4 : SCSIT results using fresh HepG2 spheroids

Batch	Control	62.5µM	125µM	250µM	500µM	1000µM
A	-	-	+	+	+	+
B	-	-	+	+	+	+
C	-	-	+	+	+	+

- 15 - indicates that no spheroid cell spreading inhibition was observed;
 + indicates that spheroid cell spreading was inhibited.

- 20 Figure 3A shows that 48 hours after exposure of a liver spheroid to propranolol at a concentration of 125 µM, no spheroid cell spreading inhibition is observed.

 However, Figure 3B shows that 48 hours after exposure of a liver spheroid to propranolol at a concentration of

250 μ M, spheroid cell spreading was inhibited.

From Table 3, it can be seen that propranolol inhibits liver spheroid cell spreading at concentrations of 250 μ M and higher.

- 5 From Table 4, it can be seen that propranolol inhibits HepG2 spheroid cell spreading at concentrations of 125 μ M and higher.

EXAMPLE 3

- 10 Freshly prepared spheroids were exposed to diclofenac at various concentrations as detailed in Tables 3 and 4, and the effects on spheroid cell spreading inhibition observed:

- 15 Table 5: SCSIT results using fresh liver spheroids

Batch	Control	0.1 μ M	1 μ M	10 μ M	100 μ M	1000 μ M
A	-	-	-	-	-	+
B	-	-	-	-	-	+
C	-	-	-	-	-	+

Table 6 : SCSIT results using fresh HepG2 spheroids

Batch	Control	0.1 μ M	1 μ M	10 μ M	100 μ M	1000 μ M
A	-	-	-	-	-	+
B	-	-	-	-	-	+
C	-	-	-	-	-	+

- 20 - indicates that no spheroid cell spreading inhibition was observed;
+ indicates that spheroid cell spreading was inhibited.

Figure 4A shows that 48 hours after exposure of a liver spheroid to diclofenac at a concentration of 100 μM , no spheroid cell spreading inhibition is observed.

However, Figure 4B shows that 48 hours after exposure of a liver spheroid to diclofenac at a concentration of 1000 μM , spheroid cell spreading was inhibited.

From Tables 5 and 6, it can be seen that diclofenac inhibits both liver spheroid and HepG2 spheroid cell spreading at concentrations of 1000 μM and higher.

EXAMPLE 4

Freshly prepared spheroids were exposed to paracetamol at various concentrations as detailed in Tables 3 and 4, and the effects on spheroid cell spreading inhibition observed:

Table 7: SCSIT results using fresh liver spheroids

Batch	Control	5 μM	50 μM	500 μM	5mM	50mM
A	-	-	-	-	-	+
B	-	-	-	-	-	+
C	-	-	-	-	-	+

Table 8 : SCSIT results using fresh HepG2 spheroids

Batch	Control	5 μM	50 μM	500 μM	5mM	50mM
A	-	-	-	-	-	+
B	-	-	-	-	-	+
C	-	-	-	-	-	+

- indicates that no spheroid cell spreading inhibition

was observed;

+ indicates that spheroid cell spreading was inhibited.

5 Figure 5A shows that 48 hours after exposure of a liver spheroid to paracetamol at a concentration of 5 mM, no spheroid cell spreading inhibition is observed.

 However, Figure 5B shows that 48 hours after exposure of a liver spheroid to paracetamol at a concentration of 50 mM, spheroid cell spreading was inhibited.

10 From Tables 7 and 8, it can be seen that paracetamol inhibits both liver spheroid and HepG2 spheroid cell spreading at concentrations of 50 mM and higher.

15 **SUMMARY**

 From the examples provided above, it is clear that when spheroids are exposed to a certain concentration of a toxicant, cell spreading is inhibited. This effect was observed with all four selected toxicants
20 using both fresh liver and HepG2 spheroids. Therefore, spheroid cell spreading inhibition is a reliable, repeatable and stable indicator of toxicity.

CLAIMS

1. An *in vitro* toxicity assay comprising:
 - 5 a) exposing a spheroid sample to a selected concentration of a compound to be assayed;
 - b) incubating the spheroid sample for a suitable period of time; and
 - 10 c) observing if spheroid cell spreading inhibition takes place.
2. An *in vitro* toxicity assay according to claim 1, wherein spheroid cell spreading inhibition indicates that, at the selected concentration, the compound has a
15 toxic effect on the spheroid cell.
3. An *in vitro* toxicity assay according to claim 1 or claim 2, wherein the spheroid cell is derived from cells selected from the group consisting of neuronal
20 cells, liver cells and retinal cells.
4. An *in vitro* assay according to any preceding claim wherein the spheroid sample is derived from a mammalian cell.
25
6. An *in vitro* toxicity assay according to claim 5, wherein the mammalian cell is a human, rodent, or porcine cell.
- 30 7. An *in vitro* toxicity assay according to any preceding claim, wherein the spheroid cell is derived from a cultured cell line.
8. An *in vitro* assay according to any preceding
35 claim, wherein the spheroid sample comprises more than one cell type.

ABSTRACT

- 5 An *in vitro* toxicity assay comprising:
- a) exposing a spheroid sample to a selected concentration of a compound to be assayed;
 - b) incubating the spheroid sample for a suitable period of time; and
 - 10 c) observing if spheroid cell spreading inhibition takes place.

FIG. 1A




FIG. 1 B




FIG. 1C



FIG. 2A




FIG. 2B




FIG. 2C



FIG. 3A



FIG. 3B




FIG. 4A




FIG. 4B



FIG. 5A




FIG. 5B



PCT 1 FEB 2003 / 000097

Paul Stora



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.